FDA Finalizes Psychedelic Clinical Trial Guidance; States Move on Ibogaine Research
FDA final guidance sets standards for psychedelic clinical trials. Federal agencies and states are advancing psilocybin and ibogaine research, and Eli Lilly is acquiring AtaiBeckley for $2.8 billion.